Personalized cancer treatment: new test aims to match patients with right drugs
NCT ID NCT03877796
Summary
This study is testing a tool called a Drug Response Predictor (DRP) that analyzes a patient's stored tumor tissue. The goal is to see if the tool can identify which experimental cancer drugs are most likely to work for individual patients with advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. The study will also look back at past treatments to see if the tool could have predicted how well those drugs worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beatson West of Scotland Cancer Centre
ACTIVE_NOT_RECRUITINGGlasgow, Scotland, G12 0YN, United Kingdom
-
Dana-Farber Cancer Institute
COMPLETEDBoston, Massachusetts, 02215, United States
-
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital
ACTIVE_NOT_RECRUITINGLondon, United Kingdom
-
OU Health Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Swedish Center for Research and Innovation
RECRUITINGSeattle, Washington, 98122, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.